S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:UBX

Unity Biotechnology (UBX) Stock Price, News & Analysis

$1.64
+0.01 (+0.61%)
(As of 03/28/2024 ET)
Today's Range
$1.58
$1.66
50-Day Range
$1.50
$1.99
52-Week Range
$1.46
$3.82
Volume
65,620 shs
Average Volume
93,521 shs
Market Capitalization
$27.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67

Unity Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
306.5% Upside
$6.67 Price Target
Short Interest
Healthy
1.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
1.48mentions of Unity Biotechnology in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2,023 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.05) to ($2.66) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.57 out of 5 stars

Medical Sector

103rd out of 938 stocks

Pharmaceutical Preparations Industry

37th out of 422 stocks

UBX stock logo

About Unity Biotechnology Stock (NASDAQ:UBX)

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

UBX Stock Price History

UBX Stock News Headlines

UBX Mar 2024 2.000 call
Unity Biotechnology Inc (UBX)
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Wedbush Upgrades Unity Biotechnology (UBX)
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
20 Foods Consumed By Longest Living People Every Day
Unity Biotechnology Inc CEO Anirvan Ghosh Sells 1,246 Shares
20 States With The Longest Life Expectancy In America
Analyst Ratings for Unity Biotechnology
See More Headlines
Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:UBX
Fax
N/A
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.67
High Stock Price Target
$10.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+306.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-59,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$240,000.00
Book Value
$4.71 per share

Miscellaneous

Free Float
15,963,000
Market Cap
$27.52 million
Optionable
Optionable
Beta
0.88
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Anirvan Ghosh Ph.D. (Age 60)
    CEO & Director
    Comp: $1.08M
  • Dr. Nathaniel E. David A.B. (Age 56)
    Ph.D., Co-Founder & Executive Director
    Comp: $40k
  • Ms. Lynne Marie Sullivan (Age 57)
    CFO & Head of Corporate Development
    Comp: $730.82k
  • Dr. Jan M. van Deursen
    Founder
  • Dr. Judith Campisi Ph.D.
    Founder
  • Mr. Daohong Zhou M.D.
    Founder
  • Mr. Nathan Guz Ph.D.
    Vice President of Operations
  • Mr. Alexander Azoy (Age 48)
    Chief Accounting Officer & Principal Accounting Officer
  • Dr. Przemyslaw Sapieha Ph.D.
    Chief Scientist
  • Mr. Alexander Hieu Nguyen J.D. (Age 47)
    General Counsel & Corporate Secretary

UBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Unity Biotechnology stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UBX shares.
View UBX analyst ratings
or view top-rated stocks.

What is Unity Biotechnology's stock price target for 2024?

2 analysts have issued 12-month price targets for Unity Biotechnology's stock. Their UBX share price targets range from $4.00 to $10.00. On average, they expect the company's share price to reach $6.67 in the next twelve months. This suggests a possible upside of 306.5% from the stock's current price.
View analysts price targets for UBX
or view top-rated stocks among Wall Street analysts.

How have UBX shares performed in 2024?

Unity Biotechnology's stock was trading at $1.93 at the beginning of 2024. Since then, UBX shares have decreased by 15.0% and is now trading at $1.64.
View the best growth stocks for 2024 here
.

When is Unity Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our UBX earnings forecast
.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) posted its earnings results on Wednesday, November, 10th. The company reported ($3.00) earnings per share for the quarter, topping the consensus estimate of ($3.60) by $0.60.

When did Unity Biotechnology's stock split?

Shares of Unity Biotechnology reverse split on Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

When did Unity Biotechnology IPO?

Unity Biotechnology (UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (4.10%), Dimensional Fund Advisors LP (0.15%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anirvan Ghosh and Jamie Dananberg.
View institutional ownership trends
.

How do I buy shares of Unity Biotechnology?

Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:UBX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners